About this term
- Quick definition
- Depression that has not responded to at least two adequate trials of standard antidepressants. Adequate means the right dose for long enough.
- Full clinical definition
- The most common operational definition is failure to respond to two antidepressant trials of adequate dose and duration (usually six to eight weeks at a therapeutic dose) within the current depressive episode. Other definitions add factors like the number of prior episodes, severity, persistence, and the use of medications from different classes. The term has no single international standard, and clinicians often use staging tools like the Maudsley Staging Method or the Massachusetts General Hospital staging method to describe degree.
- Epidemiology
- Roughly one in three patients with major depressive disorder do not reach remission after two adequate medication trials. Data from the STAR*D trial showed cumulative remission rates of about 67 percent across four sequential treatment steps, with the largest gains in the first two steps (Rush et al., 2006). The remaining group is the population usually described as having treatment-resistant depression.
- What it can feel like
- A long, often discouraging stretch of trying medications and not feeling much different. Patients often describe a loss of confidence in the system and a fear that nothing will work. Many have been told they are "trying" or "not motivated," which is rarely the actual problem.
- Why the careful name
- Many cases that look treatment-resistant turn out to be cases of incomplete prior treatment. Common reasons include subtherapeutic dosing, short trials, missed bipolar disorder, untreated medical contributors (thyroid disease, sleep apnea, anemia), ongoing substance use, ongoing trauma exposure, and unaddressed sleep problems. A thorough re-evaluation reopens many of these doors before the diagnosis is settled.
- How clinicians assess it
- A complete history of past trials (drug, dose, duration, response, side effects, and reason for stopping) is the central tool. The clinician also reviews current medical conditions, substance use, sleep, and any history of mood elevation. Lab work usually includes thyroid function and a metabolic panel. A second psychiatric opinion is sometimes appropriate before adding more medications.
- Treatment implications
- Options when the diagnosis is genuine include switching antidepressant class, augmenting with a second medication (lithium, T3, or atypical antipsychotics with evidence in depression such as aripiprazole, quetiapine, brexpiprazole), and adding therapy if not already in place. Esketamine nasal spray is FDA approved for treatment-resistant depression. Intravenous ketamine is used off-label in specialty settings. Transcranial magnetic stimulation (TMS) is FDA approved and noninvasive. Electroconvulsive therapy (ECT) is the most effective acute treatment for severe or life-threatening cases. Each option has its own risks, requirements, and evidence base, and the choice is shared between patient and prescriber.
- Related terms
- Antidepressant. Major depressive disorder. Relapse. Remission. Medication management.
- Related articles
- Treatment.
Sources
- Rush AJ, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006.
- Voineskos D, et al. Management of treatment-resistant depression: challenges and strategies. Neuropsychiatr Dis Treat. 2020.
- American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder.